Minirin Melt Tablets are ineffective for the treatment of nephrogenic diabetes insipidus.
Minirin Melt film coated tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Minirin Melt Tablets are ineffective for the treatment of nephrogenic diabetes insipidus.
Minirin Melt sublingual tablet is indicated for the treatment of-
By mimicking the actions of endogenous ADH, desmopressin acts as a selective agonist of V2 receptors expressed in the renal collecting duct (CD) to increase water re-absorption and reduce urine production.
Although the pressor activity of Minirin Melt are very low compared to its antidiuretic activity, large doses of Minirin Melt Tablets should be used with other pressor agents only with careful patient monitoring.
Desmopressin Acetate Tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of Desmopressin Acetate Tablets.
Infrequently, large doses of the intranasal formulations of Minirin Melt Tablets and Minirin Melt Injection have produced transient headache, nausea, flushing and mild abdominal cramps. These symptoms have disappeared with reduction in dosage.
There have been no controlled studies in nursing mothers. Caution should be exercised when desmopressin acetate is administered to nursing mothers.
Synthetic analogue of ADH
Store at temperature not exceeding 30°C in a dry place. Protect from light and moisture.
